Table 1 Patient characteristics
From: A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients
PSA (ng/mL) | |
Median (range) | 17.0 (1.4–35.0) |
No. Gleason score (%) | |
≤ 3 + 4 | 5 (25%) |
≥ 4 + 3 | 15 (75%) |
No. clinical stage (%) | |
cT1 | 5 (25%) |
cT2 | 8 (40%) |
cT3 | 7 (35%) |